Dren Bio Announces $350 Million Financing to Advance Dibotatug Toward Commercialization and Accelerate Development of Broader Pipeline
“We founded Dren Bio with a simple vision: pursue novel science to develop medicines that meaningfully improve the lives of patients with devastating diseases and few treatment options. Seeing dibotatug advance to this late stage of development, alongside a clinically validated platform that continues to generate promising new therapies, is deeply gratifying and reflects the vision that inspired us from day one,” said Nenad Tomasevic, Ph.D., Chief Executive Officer and Founder of Dren Bio. “Today’s financing, supported by an exceptional group of new and existing investors who share our mission is a proud moment for the team, and positions us to accelerate the development of novel therapies for a range of diseases.”
Share:
More News
“We’ve already seen what subcutaneous amivantamab may offer patients with head and neck cancer after their disease has progressed. Now, we see the potential impact of using this approach earlier in recurrent or metastatic disease,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. “Our
“Meaningful progress has been made in the treatment of pancreatic cancer and we are proud that Tumor Treating Fields therapy is one of the new options available to patients. However, advanced pancreatic cancer remains one of the most difficult cancers to treat,” said Uri Weinberg, MD, PhD, Chief Medical and
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated
“Multiple myeloma is a chronic blood cancer that can reshape a person’s life. Patients deserve therapeutic options that are not only effective, but also support the realities of when, where and how they receive treatment,” said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology,